| Indicatie: | Adult (≥18 years old) participants with primary ITP who had an insufficient response to or relapsed after first-line treatment with corticosteroids ±IVIG, and who have a platelet count below 30 G/L, for whom eltrombopag is clinically indicated as per physician’s discretion and with no contraindication to receive eltrombopag. |
| Studie: | VAYHIT2 |
| A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2) |
| Open in: | LUMC |
| Contact: | j.j.zwaginga@lumc.nl |
| Status: | OPEN |
|
| Indicatie: | Adult patients with relapsed or refractory HLA-A*02:01-positive NPM1-
mutated AML.
|
| Studie: | LUMC NPM1-TCR studie |
| A phase I/II trial of MB-dNPM1-TCR.1 in HLA-A*02:01-positive patients with relapsed or
refractory NPM1-mutated AML to determine safety and obtain first data on efficacy
|
| Open in: | LUMC |
| Contact: | C.J.M.Halkes@lumc.nl |
| Status: | OPEN |
|
| Indicatie: | Patients ≥ 18 years of age with previously untreated CLL in need of treatment |
| Studie: | BGB 11417-301 |
| A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | MM Participants with Relapsed or Refractory Myeloma who Have Received 1-4 Prior Lines of Therapy Including an AntiCD38 Antibody and Lenalidomide |
| Studie: | MonumenTAL-6 |
| A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (TalP), Talquetamab in Combination with Teclistamab (TalTec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1-4 Prior Lines of Therapy Including an AntiCD38 Antibody and Lenalidomide |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | DLBCL (NOS), High-grade B-cell lymphoma (MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (DHL/THL) and FL3B, T-cell/histocyte rich B-cell lymphoma, Primary mediastinal B-cell lymphoma, transformed lymphoma (transformed follicular) and R/R after at least 2 lines of systemic therapy.
Age >17 jr |
| Studie: | HOVON161 |
| A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma |
| Open in: | LUMC |
| Contact: | J.S.P.Vermaat@lumc.nl |
| Status: | OPEN |
|
| Indicatie: | Autoimmune Hemolytic Anemia |
| Studie: | MOM-M281-006 Energy |
| Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension” |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | CLOSED |
|
| Indicatie: | rrDLBCL |
| Studie: | LOTIS-5 ADCT402-311 |
| A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5).
|
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Relapsed or Refractory MM |
| Studie: | Excaliber (CC-220-MM-002) |
| A Ph III, Randomized, Multicnenter, Ope-Label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberdD) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) IN Subjects with Relapsed or REfractroy MM (RRMM) |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Relapsed or Refractory HL
Leeftijd: ≥ 18 jr |
| Studie: | HOVON 164 Tigerr |
| Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation in Patients in Metabolic Complete Response (TIGERR-HL) |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | DLBCL
leeftijd 18-80 jr |
| Studie: | M20-621 |
| A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in
Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell
Lymphoma (DLBCL) (EPCORE DLBCL-2) |
| Open in: | HMC
LUMC |
| Contact: | l.te.boome@haaglandenmc.nl; j.s.p.vermaat@lumc.nl |
| Status: | CLOSED |
|
